Trial Profile

Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL 2

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infigratinib (Primary)
Indications Achondroplasia
Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
Acronyms PROPEL2
Sponsors QED Therapeutics

Most Recent Events

26 Mar 2025 Status changed from active, no longer recruiting to completed.
18 Nov 2024 Results presented in the BridgeBio Media Release.
18 Nov 2024 According to BridgeBio media release, Primary endpoint (Change from baseline in annualized height velocity) has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com